Axsome Therapeutics, Inc. (AXSM) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Axsome Therapeutics, Inc. (AXSM): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 42/100 — a percentile rank of Axsome Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $9.5B |
| P / S | 12.3× |
| EV / EBITDA | -52.5× |
| Gross margin | 93.2% |
| Operating margin | -24.0% |
| Net margin | -24.7% |
| Return on equity | -230.1% |
| ROIC | 471.7% |
| Revenue growth | 56.9% |
| Debt / equity | 2.4× |
| Dividend yield | 0.0% |
Is Axsome Therapeutics, Inc. overvalued? P/S looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Axsome Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact